Let me say this about my previous post. The criti

Let me say this about my previous post. The criticism of poor sales during qtr 3 is by all means not directed at current Biel staff who I believe have done all that can be expected in partnering with distributers who gladly accepted the products to include among the hundreds they offer the medical community and public. Their priorities are not as desperate as Biel. They are already making billions with what they offer and Biel just adds another opportunity for possibly more revenue. So what incentives are offered to increase sales of Biel's products. Are they going to spend a lot on advertising or marketing Biel or just allow the market to slowly accept the products as recommended from doctors in the know or word of mouth from those that tried the products. Of course as shareholders we would like a campaign to enlighten the world that there is a viable alternative to opioids that actually is beneficial to those that suffer with pain. So Biel's QTR 3 sales were disappointing as compared to SPLY. I think QTR 4 will be something we can all look forward to if the big 975K order is filled and is also supplemented by a lot more orders from the other sources. Good times are ahead in 2023. Hold tight my friends its coming. We can and should expect a financial orgasm!